Immunochemical Techniques in Natural Products Chemistry: Isolation and Structure Determination of a Novel Indole-Diterpenoid Aided by TLC-ELISAgram

Christopher O. Miles,*,[†] Alistair L. Wilkins,[‡] Ian Garthwaite,[†] Richard M. Ede,[‡] and Sarah C. Munday-Finch[†]

New Zealand Pastoral Agriculture Research Institute Ltd, Ruakura Agricultural Research Centre, Private Bag 3123, Hamilton, New Zealand, and Chemistry Department, The University of Waikato, Private Bag 3105, Hamilton, New Zealand

Received April 17, 1995[®]

Paxinorol, a novel modified indole-diterpenoid believed to be derived from paxilline, was detected with the recently-developed TLC-ELISAgram technique as a trace contaminant of a paxillinecontaining extract from the fungus Penicillium paxilli Bainier. Paxinorol was isolated by column chromatography, and its structure was determined by ¹H and ¹³C NMR spectroscopy and mass spectrometry.

Introduction

We have developed enzyme-linked immunosorbent assays (ELISAs) for a number of indole-diterpenoids associated with the neurotoxic disease of livestock known as ryegrass staggers, including an ELISA for paxilline.¹ The immunization and selection procedures were such that the anti-paxilline monoclonal antibody used in this immunoassay was capable of recognizing an array of compounds structurally related to paxilline. Recently, Pestka² published details of an immunoblot technique coupled to TLC analysis (TLC-ELISAgram). The method, as reported, was essentially a quantitative technique. However, we anticipated that, by using antibodies with broad specificity, TLC-ELISAgram would be an ideal technique for identifying small quantities of structurallyrelated compounds whose existence in a sample had not previously been suspected.

We now report application of the TLC-ELISAgram technique to the analysis of an extract from Penicillium paxilli Bainier, leading to the identification of a trace contaminant. The structure of this contaminant, which we name paxinorol (2), was similar to that of the indolediterpenoid skeleton of paxilline (1), but with a highly modified F-ring.

Results and Discussion

TLC of the P. paxilli extract indicated that the major component $(R_f \ 0.8)$ was paxilline. This was confirmed by isolation of this component (200 mg) and comparison of its ¹H and ¹³C NMR and mass spectra with those reported for paxilline in the literature.³ Several minor spots were also visible on the TLC plate. The ELISAgram immunoblot procedure revealed that one of these spots, at R_f 0.2, cross-reacted with the anti-paxilline antibody. Consideration of the known cross-reactivity of this antibody¹ suggested that this spot was likely to be associated with a compound containing the intact rings A-E of paxilline.



The compound, which we name paxinorol (2), was isolated by flash chromatography as a colorless solid (1 mg). Because of the small quantity of 2 available, mp data were not obtained. Mass spectrometry revealed a prominent ion at m/z 182, consistent with the presence of an intact ring A-C system of paxilline.⁴ The mass of the molecular ion was consistent with a molecular formula of $C_{24}H_{27}NO_3$. Acetylation gave a more mobile compound, the mass spectrum of which also showed a prominent ion at m/z 182 and a molecular ion consistent with a monoacetate with the molecular formula $C_{26}H_{29}$ -NO₄. Thus, 2 contained one primary or secondary hydroxyl group somewhere other than in rings A-C and a more-or-less intact ring A-E system of the type found in paxilline (1).

Because of the limited solubility of paxinorol in CDCl₃ or $(CD_3)_2CO$, the ¹H and ¹³C NMR spectra of paxilline (1) and paxinorol (2) were obtained with C_5D_5N as the solvent. A complete assignment of the ¹H and ¹³C NMR resonances of paxilline (1) was obtained (Table 1) by standard methodology.³

The ¹³C NMR spectrum of paxinorol comprised nine quaternary, eight methine, five methylene, and two methyl carbons. Although the positions of the resonances

^{*} Author to whom correspondence should be addressed (phone +64-7-8385041; facsimile +64-7-8385189; email milesc@agresearch.cri.nz).

[†] Ruakura Agricultural Research Centre.

[‡] The University of Waikato.

[®] Abstract published in Advance ACS Abstracts, August 15, 1995. (1) Garthwaite, I.; Miles, C. O.; Towers, N. R. Immunological detection of the indole-diterpenoid tremorgenic mycotoxins. In Pro-ceedings of the Second International Symposium on Acremonium/Grass Interactions, February, 1993; Hume, D. E., Latch, G. C. M., Easton, H. S., Eds.; AgResearch, Grasslands Research Centre: Palmerston North, New Zealand, pp 77-80 (ISSN 1052-5181). (2) Pestka, J. J. J. Immunol. Methods 1991, 136, 177.

⁽³⁾ Miles, C. O.; Wilkins, A. L.; Gallagher, R. T.; Hawkes, A. D.; Munday, S. C.; Towers, N. R. J. Agric. Food Chem. 1992, 40, 234.

⁽⁴⁾ Gallagher, R. T.; Clardy, J.; Wilson, B. J. Tetrahedron Lett. 1980, 21, 239.

6068 J. Org. Chem., Vol. 60, No. 19, 1995

Table 1. ¹H and ¹³C NMR Assignments (δ) and ¹J(¹³C⁻¹H) Coupling Constants (\pm 1 Hz) for Paxilline (1) and Paxinorol (2) in C₅D₅N

	paxilline (1)				paxinorol (2)			
	¹³ C	¹Hα	¹ Ηβ	¹ J. (¹³ C- ¹ H)	¹³ C	¹Hα	¹ Hβ	¹ <i>J</i> - (¹³ C- ¹ H)
2	153.6				154.0			
3	51.4				51.5			
4	43.4				43.5			
5	27.3	3.00	1.97		27.8	3.03	1.94	
6	29.0	2.25	1.96		28.7	2.36	1.74	
7	73.6	5.16		144.5	46.6	3.73		135.1
9	84.2	3.81		139.1	80.9	00	4.30	138.4
10	198.9	0.01			208.9			20011
11	119.6	5.14		163.9	121.7	5.99		169.1
12	169.9				183.4			
13	76.7				74.8			
14	33.9	1.95			33.7	1.97		
		-1.99^{a}				-2.00^{a}		
15	21.5	2.28	1.73		21.9	2.34	1.74	
16	50.2		3.01		50.4		3.03	
17	27.6	2.62	2.85		27.8	2.62	2.85	
18	116.6				116.5			
19	126.0				126.0			
20	118.7	7.29		156.9	118.7	7.24		156.4
21	119.4	7.24		156.9	119.4	7.21		156.9
22	120.2	7.74		156.9	120.2	7.71		157.2
23	112.4	7.53		156.9	112.4	7.56		156.7
24	141.3				141.3			
25	16.9	1.69		127.2	17.0	1.73		127.5
26	19.4	1.18		125.5	19.3	1.12		128.6
27	72.0							
28	25.6	1.52						
29	26.7	1.54						
13-OH		6.59				6.64		
9-OH		5.23				nd^b		
NH		11.59				11.56		

^a Broad multiplet ^b nd = not detected.

for C-2 to C-6 and C-14 to C-26 were virtually identical for 1 and 2, those for C-7 to C-13 differed substantially. Furthermore, resonances attributable to the hydroxyisopropyl side chain present at C-9 of 1 (C-27 to C-29) were absent in 2. Thus, with exception only of the ring F resonances, the majority of the ¹³C NMR resonances of paxinorol were very similar to those for paxilline (1).

Differences between the ¹H NMR spectra of paxilline and paxinorol were also consistent with paxinorol being a tris-nor paxilline-like indole-diterpenoid. For example, four methyl signals appeared in the ¹H NMR spectrum of paxilline, but only two methyl resonances were present in the ¹H NMR spectrum of paxinorol. The absence of the methyl group signals attributable to the hydroxyisopropyl group of 1, together with the 58 mass unit difference between paxilline and paxinorol, suggested that paxinorol might have been derived from paxilline by loss of a molecule of acetone, possibly via the retroaldol reaction that is probably responsible for the formation of the ion at m/z 377 in the mass spectrum of paxilline. However, a more detailed analysis of ¹H and ¹³C NMR data discounted the possibility that paxinorol was produced by a retro-aldol reaction of paxilline.

Notably, the two-dimensional ${}^{13}\text{C}{}^{-1}\text{H}$ correlated NMR spectrum of paxinorol revealed that the two ring F methine carbons (46.6 and 80.9 ppm) correlated with proton signals at 3.73 (H-7) and 4.30 (H-9) ppm, respectively. In the COSY spectrum, the proton signal at 3.73 ppm (H-7) correlated strongly with resonances at 2.36 (H-6 α), 1.74 (H-6 β), and 5.99 (H-11) ppm, respectively, and weakly to a signal at 4.30 ppm (H-9).

The foregoing ¹H and ¹³C NMR data indicate that C-9 of paxinorol is oxygenated, but that C-7 is not. In particular, the C-7 and H-7 resonances of paxilline occur



Figure 1. ¹³C NMR chemical shifts for C-10 to C-12 of 1 and 2 and for the equivalent resonances of 2-cyclohexen-1-one (3) and 2-cyclopenten-1-one (4) (data for 3 and 4 from ref 5).

at 73.6 and 5.16 ppm, respectively, whereas the equivalent resonances of paxinorol (2) occur at 46.6 and 3.73 ppm. On the other hand, the C-9 (80.9 ppm) and H-9 (4.30 ppm) resonances of 2 are similar to those of 1 (84.2 and 3.81 ppm, respectively), consistent with oxygenation at C-9. Paxinorol (2) therefore lacks the ether bridge present at O-8 of 1. These observations suggested the presence in paxinorol of a direct C-7–C-9 bond and a hydroxyl group at C-9, with a five-membered ring F. The coupling constant exhibited by H-9 (J = 3.2 Hz), which the COSY spectrum indicated to arise from coupling with H-7 (see above), was also consistent with a ³J coupling (rather than a ⁴J coupling) between H-7 and H-9.

Comparison (Figure 1) of the C-10 and C-12 resonances established for paxinorol (2) (208.9 and 183.4 ppm, respectively) and for paxilline (1) (198.9 and 169.9 ppm, respectively) with those reported⁵ for the C-1 and C-3 resonances of 2-cyclopenten-1-one (4) (209.8 and 165.3 ppm, respectively) and 2-cyclohexen-1-one (3) (199.0 and 150.6 ppm, respectively) supports this proposal, because the downfield shifts experienced by C-1 (+10.8 ppm) and C-3 (+14.7 ppm) of 4, relative to 3, are analogous to those exhibited by C-10 (+10.0 ppm) and C-12 (+13.5 ppm) of 2, relative to 1.

Additionally, the ${}^{1}J({}^{13}C-{}^{1}H)$ coupling constants determined for C-7 (135.1 Hz) and C-9 (138.4 Hz) in paxinorol are consistent with the proposed structure 2, the equivalent ${}^{1}J({}^{13}C-{}^{1}H)$ coupling constants for paxilline being 144.5 Hz and 139.1 Hz, respectively. Comparison of the C-11 ${}^{1}J$ coupling constants of paxinorol (169.1 Hz) and paxilline (163.9 Hz) also suggests a five-membered cyclopentenone-type ring system in paxinorol (2), rather than a six-membered F-ring such as is present in paxilline (1), because it is well established that in small ring systems a decrease in ring size is accompanied by an increase in coupling constant—an effect ascribed to the increased s-character of the hybrid carbon orbitals in the ring.⁵

The stereochemistry at C-9 of paxinorol was established in NOE difference experiments. Irradiation of H-9 (4.30 ppm) caused NOE enhancement of H-6 β (3.9%) and H-7 α (2.1%), whereas irradiation of H-6 β (1.74 ppm) enhanced H-6 α (8.1%), H-26 (i.e. the 4 β -Me group) (1.0%), and H-9 (2.0%). Irradiation of H-7 α (3.73 ppm) enhanced the H-9 (2.4%), H-5 α (1.0%), H-6 α (3.9%), and 13-OH (2.6%) resonances, whereas irradiation of H-6 α (2.36 ppm) enhanced H-6 β (18.5%) and H-7 α (4.4%), but not

⁽⁵⁾ Breitmaier, E.; Voelter, W. Carbon-13 NMR Spectroscopy. High Resolution Methods and Applications in Organic Chemistry and Biochemistry, 3rd ed.; VCH Verlagsgesellschaft mbH: D-69040, Weinheim, Federal Public of Germany, 1987.

H-9. It follows from those observations that H-9 is β -oriented and that the 9-hydroxyl group is therefore α -oriented. The observation of an NOE between H-9 and H-6 β is of paramount importance in defining the C-9 stereochemistry of paxinorol, because molecular models clearly demonstrated that had H-9 been α -oriented it would have been too distant from H-6 β for an NOE to have been observed.

Because the resonances of H-6 α and H-6 β were coincident with those of H-15 α and H-15 β , respectively, the preceding NOE experiments also resulted in enhancements of suitably oriented ring C/D protons. Fortunately, none of the NOEs originating from H-15 α , or from H-15 β , interfered with the detection of the NOEs originating from H-6 α , H-6 β , H-7 α , and H-9, because all of these protons are too distant from H-15 α and H-15 β for mutual NOEs to be observed.

The structure of paxinorol is therefore established as 2, which is formally derived from 1 by loss of acetone. It is not possible to be certain that 2 is a natural product because, due to the prolonged storage prior to its isolation, it may have been produced abiotically from the much more abundant 1. Nevertheless, the identification of 2 by TLC-ELISAgram, and its subsequent isolation, illustrates the considerable potential that exists for use of this and other immunochemical techniques in natural products chemistry.

Experimental Section

General Methods. TLC was performed on plates coated with silica gel 60 F_{254} (0.2 mm) with CH₃OH-CHCl₃ (1:19) as the eluent, and compounds were detected by their fluorescencequenching upon irradiation at 254 nm. Flash column chromatography⁶ was performed on silica gel with CH₃OH-CH₂Cl₂ (1:24 for paxinorol; 1:49 for paxinorol acetate) as the eluent. Paxinorol was acetylated with acetic anhydride-pyridine (1: 1, 1 mL) overnight before removal of the solvent in vacuo (toluene azeotrope) and purification by column chromatography. P. paxilli (FRR1900) was grown in culture and crude paxilline extracted from the mycelium as previously described.⁷ This extract was defatted by partitioning between petroleum spirit and ethanol-water (1:4), and the ethanolic extract was evaporated to dryness in vacuo. The extract was stored in the dark at 4 °C for 1 year prior to isolation of 2. Authentic paxilline was available from earlier work in our laboratory.³ The TLC-ELISAgram was obtained by the method of Pestka,² with a monoclonal anti-paxilline antibody generated by immunization of mice with conjugates of paxilline O-(carboxymethyl)oxime.¹ Briefly, a nitrocellulose sheet was coated with antibody by incubating it with the anti-paxilline antibody overnight, and additional protein-binding sites were blocked by incubation (1 h) with 1% bovine serum albumin. The developed TLC plate was air-dried and contact-blotted against the antibody-coated nitrocellulose sheet. After capture of cross-reacting material by the antibody, the nitrocellulose sheet was developed by incubation with a paxilline-enzyme conjugate. Incubation with the substrate then revealed areas of the sheet containing cross-reacting compounds as colorless regions against a uniformly colored background.

Nuclear Magnetic Resonance Spectroscopy. ¹H and ¹³C NMR spectra were obtained at 300 K from C_5D_5N solutions unless otherwise stated, at 300 and 75 MHz, respectively. Carbon signal multiplicities (s, d, t, or q) were determined using the DEPT135 sequence. NOE difference experiments were performed with an irradiation power level of 40 L. NOE difference spectra were obtained by subtraction of an off-resonance control FID from an irradiated FID and Fourier transformation of the resulting difference-FID. Two-dimensional COSY and double quantum-filtered COSY spectra were determined in absolute value mode, and the ¹³C-¹H-correlated spectrum was determined in phase-sensitive mode.

Paxinorol (2). Paxinorol was isolated as a colorless solid: ¹H NMR δ 1.12 (H-26), 1.73 (H-25), 1.64–1.79 (m, H-6 β and H-15 β), 1.88–2.05 (m, H-5 β , H-14 α , and H-14 β), 2.29–2.43 (m, H-6 α and H-15 α), 2.62 (dd, J = 13.0, 11.0 Hz, H-17 α), 2.85 (dd, J = 13.0, 6.1 Hz, H-17 β), 2.93–3.10 (m, H-5 α and H-16 β), 3.73 (br t, J = 10.6 Hz, H-7), 4.30 (d, J = 3.2 Hz, H-9), 5.99 (br d, J = 1.8 Hz, H-11), 6.64 (s, 13-OH), 7.21–7.24 (m, H-20 and H-21), 7.56 (m, H-23), 7.71 (m, H-22), 11.56 (br s, NH); ¹³C NMR and ¹³C–¹H two-dimensional correlations, see Table 1; EI-MS m/z (rel intensity) 377.1966 (M⁺, calcd m/z 377.1992 for C₂₄H₂₇NO₃, 6), 362 (100), 344 (59), 182 (97). ¹H and ¹³C NMR assignments for **2** are reported in Table 1.

Paxinorol 9-acetate, a colorless oil, was prepared by acetylation of **2**: ¹H NMR (CDCl₃) δ 1.02 (H-26), 1.37 (H-25), 2.16 (CH₃COO), 4.91 (d, J = 3.2 Hz, H-9), 5.89 (br d, J = 1.7 Hz, H-11), 7.08 (m, H-21 and H-22), 7.30 (m, H-23), 7.44 (m, H-20), 7.72 (br s, NH); EI-MS m/z (rel intensity) 419.2128 (M⁺, calcd m/z 419.2098 for C₂₆H₂₉NO₄, 6), 404 (78), 386 (53), 182 (100).

Acknowledgment. We thank M. E. di Menna and C. M. Johnson for assistance with fungal cultures and P. T. Holland and D. E. McNaughton for obtaining mass spectra.

Supporting Information Available: ¹³C NMR spectra of 1 and 2 and cross-reactivity data for the anti-paxilline antibody (4 pages). This material is contained in libraries on microfiche, immediately follows this article in the microfilm version of the journal, and can be ordered from the ACS; see any current masthead page for ordering information.

JO950717I

⁽⁶⁾ Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923.
(7) Ibba, M.; Taylor, S. J. C.; Weedon, C. M.; Mantle, P. G. J. Gen. Microbiol. 1987, 133, 3109.